Open AccessCurrent management approaches to patients with atrial fibrillation and percutaneous coronary intervention
Author(s) -
О. Л. Барбараш,
В. В. Кашталап
Publication year - 2019
Publication title -
medicinskij alfavit
Language(s) - English
Resource type - Journals
eISSN - 2949-2807
pISSN - 2078-5631
DOI - 10.33667/2078-5631-2019-2-30(405)-12-17
Subject(s) - antithrombotic , medicine , percutaneous coronary intervention , atrial fibrillation , clopidogrel , cardiology , coronary heart disease , intervention (counseling) , intensive care medicine , aspirin , myocardial infarction , psychiatry
In this review are provided relevant positions of the American and European clinical guidelines for antithrombotic therapy in the patients with a combination of atrial fibrillation and coronary heart disease with percutaneous coronary intervention. Similarities and distinctions of positions of two expert communities were discussed. In addition, the evidence-based positions concerning the choice of the optimal antithrombotic therapy are noted. Primary positions of a clopidogrel when choosing the antiagregants for double or triple antithrombotic therapy were designated.